{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:34:56Z","timestamp":1777865696461,"version":"3.51.4"},"reference-count":77,"publisher":"The Royal Society","issue":"1949","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"RGC"},{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Seasonal influenza is a widespread acute respiratory infection that causes significant illness and death worldwide. Two major antiviral classes are neuraminidase inhibitors (NAIs) and polymerase inhibitors. NAIs, including oseltamivir, zanamivir, peramivir and laninamivir, block viral release, while polymerase inhibitors such as baloxavir disrupt viral RNA replication. Early administration within 48 h of symptom onset reduces illness duration, severity and complications, particularly in high-risk groups. Oseltamivir is the most widely studied NAI, demonstrating reduced viral shedding, faster symptom resolution and lower complication rates, though gastrointestinal side effects are common. Higher doses generally do not improve outcomes compared to standard dosing. Zanamivir is more effective against influenza B and is inhibitory for most influenza A viruses resistant to oseltamivir, but the inhaled formulation is less suitable for patients with severe illness or airway disease. Intravenous (IV) zanamivir is approved for hospitalized influenza patients in some countries. Peramivir offers IV treatment options, while laninamivir is mainly used in Japan. Baloxavir shows superior viral load reduction and comparable symptom relief to oseltamivir in outpatients, though resistance variants can emerge. Favipiravir and newer polymerase inhibitors are under investigation. Combination therapies may enhance recovery, with limited evidence. Overall, timely antiviral use is critical to reducing influenza\u2019s burden.<\/jats:p>\n                  <jats:p>This article is part of the Theo Murphy meeting issue \u2018Evaluating anti-infective drugs\u2019.<\/jats:p>","DOI":"10.1098\/rstb.2024.0344","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:16:50Z","timestamp":1777533410000},"source":"Crossref","is-referenced-by-count":0,"title":["Antiviral treatment for influenza"],"prefix":"10.1098","volume":"381","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4382-2445","authenticated-orcid":false,"given":"David S.","family":"Hui","sequence":"first","affiliation":[{"name":"The Chinese University of Hong Kong Faculty of Medicine 1 , , ,","place":["Shatin, New Territories, Hong Kong"],"department":["Department of Medicine and Therapeutics"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"175","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2026043003163586200_R1","unstructured":"WHO\n          . 2025Influenza (seasonal). Seehttps:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal) (accessed1-December-2025)."},{"key":"2026043003163586200_R2","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00040-22","article-title":"Antiviral approaches against influenza virus","volume":"36","author":"Kumari","year":"2023","journal-title":"Clin. Microbiol. Rev."},{"key":"2026043003163586200_R3","unstructured":"US\n              CDC\n            \n          . 2025Treating flu with antiviral drugs.Seehttps:\/\/www.cdc.gov\/flu\/treatment\/antiviral-drugs.html (accessed8-April-2025)."},{"key":"2026043003163586200_R4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(22)00982-5","article-title":"Influenza","volume":"400","author":"Uyeki","year":"2022","journal-title":"Lancet"},{"key":"2026043003163586200_R5","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70002","article-title":"Comparison of the effectiveness of baloxavir and oseltamivir in outpatients with influenza B","volume":"18","author":"Takazono","year":"2024","journal-title":"Influenza Other Respir. Viruses"},{"key":"2026043003163586200_R6","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jama.282.13.1240","article-title":"Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment","volume":"282","author":"Hayden","year":"1999","journal-title":"J. Am. Med. Assoc."},{"key":"2026043003163586200_R7","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(00)02288-1","article-title":"Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group","volume":"355","author":"Nicholson","year":"2000","journal-title":"Lancet"},{"key":"2026043003163586200_R8","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US oral neuraminidase study group","volume":"283","author":"Treanor","year":"2000","journal-title":"J. Am. Med. Assoc."},{"key":"2026043003163586200_R9","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/523584","article-title":"Toronto invasive bacterial diseases network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada","volume":"45","author":"McGeer","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"2026043003163586200_R10","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1183\/09031936.00169714","article-title":"Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients","volume":"45","author":"Lee","year":"2015","journal-title":"Eur. Respir. J."},{"key":"2026043003163586200_R11","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/cid\/ciz634","article-title":"Effect of oral oseltamivir on virological outcomes in low-risk adults with influenza: a randomized clinical trial","volume":"70","author":"Beigel","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"2026043003163586200_R12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"2026043003163586200_R13","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/cid\/ciz101","article-title":"Effect of early oseltamivir treatment on mortality in critically ill patients with different types of influenza: a multiseason cohort study","volume":"69","author":"Lytras","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"2026043003163586200_R14","first-page":"1896","article-title":"Timing of influenza antiviral therapy and risk of death in adults hospitalized with influenza-associated pneumonia, influenza hospitalization surveillance network (FluSurv-NET)","volume":"69","author":"Tenforde","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"2026043003163586200_R15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejim.2020.12.010","article-title":"Neuraminidase inhibitors are effective and safe in reducing influenza complications: meta-analysis of randomized controlled trials","volume":"86","author":"Tejada","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"2026043003163586200_R16","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet"},{"key":"2026043003163586200_R17","first-page":"18","article-title":"Evaluation of oseltamivir used to prevent hospitalization in outpatients with influenza: a systematic review and meta-analysis","volume":"184","author":"Hanula","year":"2024","journal-title":"J. Am. Med. Assoc. Intern. Med."},{"key":"2026043003163586200_R18","first-page":"116","article-title":"Oseltamivir may or may not reduce hospitalizations","volume":"184","author":"Uyeki","year":"2024","journal-title":"J. Am. Med. Assoc. Intern. Med."},{"key":"2026043003163586200_R19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmi.2014.10.011","article-title":"Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children","volume":"21","author":"Jones","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"2026043003163586200_R20","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/cid\/cit597","article-title":"A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza A and B infections","volume":"57","author":"Lee","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"2026043003163586200_R21","doi-asserted-by":"crossref","first-page":"f3039","DOI":"10.1136\/bmj.f3039","article-title":"Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial","volume":"346","author":"South East Asia Infectious Disease Clinical Research Network","year":"2013","journal-title":"Br. Med. J."},{"key":"2026043003163586200_R22","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70109","article-title":"Pharmacodynamic effect of different dosage regimes of oseltamivir in severe influenza patients requiring mechanical ventilation: a multicentre randomised controlled trial","volume":"19","author":"Wong","year":"2025","journal-title":"Influenza Other Respir. Viruses"},{"key":"2026043003163586200_R23","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/bcp.14523","article-title":"Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK\/PD analysis and drug-disease modelling for dosing regimen optimization","volume":"87","author":"Sturm","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2026043003163586200_R24","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1473-3099(21)00469-2","article-title":"Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial","volume":"22","author":"Kumar","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"2026043003163586200_R25","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf439","article-title":"Effects of baloxavir marboxil plus neuraminidase inhibitor vs neuraminidase inhibitor in high-risk patients hospitalized with severe influenza: a post hoc analysis of the FLAGSTONE trial","volume":"12","author":"Yan","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"2026043003163586200_R26","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","article-title":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically Ill patients with influenza virus infection","volume":"221","author":"Wang","year":"2020","journal-title":"J. Infect. Dis."},{"key":"2026043003163586200_R27","doi-asserted-by":"crossref","first-page":"105657","DOI":"10.1016\/j.antiviral.2023.105657","article-title":"The combined effect of oseltamivir and favipiravir on influenza A virus evolution in patients hospitalized with severe influenza","volume":"216","author":"Mu","year":"2023","journal-title":"Antiviral Res."},{"key":"2026043003163586200_R28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107281","article-title":"Zanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant","volume":"64","author":"Euzen","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"2026043003163586200_R29","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13542","article-title":"Baloxavir treatment of oseltamivir-resistant influenza A\/H1pdm09 in two immunocompromised patients","volume":"23","author":"Macesic","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"2026043003163586200_R30","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S1473-3099(17)30476-0","article-title":"Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Beigel","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"2026043003163586200_R31","unstructured":"REMAP-CAP\n          . 2025A randomised, embedded, multi-factorial, adaptive platform trial for community-acquired pneumonia. Seehttps:\/\/www.remapcap.org\/ (accessed8-April-2025)."},{"key":"2026043003163586200_R32","unstructured":"Recovery Trial\n          . 2025Seehttps:\/\/www.ox.ac.uk\/news\/2023-10-31-recovery-trial-expands-investigate-treatments-influenza (accessed8-April-2025)."},{"key":"2026043003163586200_R33","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/cid\/ciac217","article-title":"Inhaled zanamivir vs oral oseltamivir to prevent influenza-related hospitalization or death: a nationwide population-based quasi-experimental study","volume":"75","author":"Su","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"2026043003163586200_R34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jinf.2007.09.002","article-title":"A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B","volume":"56","author":"Kawai","year":"2008","journal-title":"J. Infect."},{"key":"2026043003163586200_R35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/509925","article-title":"Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children","volume":"44","author":"Sugaya","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"2026043003163586200_R36","doi-asserted-by":"crossref","first-page":"g2547","DOI":"10.1136\/bmj.g2547","article-title":"Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments","volume":"348","author":"Heneghan","year":"2014","journal-title":"Br. Med. J."},{"key":"2026043003163586200_R37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199936001-00001","article-title":"Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers","volume":"36 (Suppl. 1)","author":"Cass","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"2026043003163586200_R38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/irv.12947","article-title":"Zanamivir aqueous solution in severe influenza: a global compassionate use program, 2009-2019","volume":"16","author":"Wang-Jairaj","year":"2022","journal-title":"Influenza Other Respir. Viruses"},{"key":"2026043003163586200_R39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2213-2600(16)30435-0","article-title":"Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial","volume":"5","author":"Marty","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"2026043003163586200_R40","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038463","article-title":"Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances","volume":"11","author":"Beigel","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"2026043003163586200_R41","doi-asserted-by":"crossref","DOI":"10.3390\/ph16010085","article-title":"Successful treatment of complicated influenza A(H3N2) virus infection and rhabdomyolysis with compassionate use of IV zanamivir","volume":"16","author":"Alchikh","year":"2023","journal-title":"Pharmaceuticals"},{"key":"2026043003163586200_R42","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1002\/ccr3.2499","article-title":"Severe myocarditis due to influenza A(H1N1)pdm09 viral infection in a young woman successfully treated with intravenous zanamivir: a case report","volume":"7","author":"Mazzitelli","year":"2019","journal-title":"Clin. Case Rep."},{"key":"2026043003163586200_R43","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4530-1","article-title":"Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series","volume":"19","author":"Torti","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"2026043003163586200_R44","article-title":"Clinical, virological and immunological features from patients infected with re-emergent avian-origin human h7n9 influenza disease of varying severity in Guangdong Province","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS ONE"},{"key":"2026043003163586200_R45","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1183\/09031936.00006414","article-title":"Severe influenza A H7N9 pneumonia with rapid virological response to intravenous zanamivir","volume":"44","author":"Ho","year":"2014","journal-title":"Eur. Respir. J."},{"key":"2026043003163586200_R46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10156-012-0460-1","article-title":"A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases","volume":"19","author":"Watanabe","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"2026043003163586200_R47","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jiac.2022.03.008","article-title":"Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate: a study of the 2017\/18 and 2018\/19 seasons and comparison with the 2011\/12 to 2016\/17 Japanese influenza seasons","volume":"28","author":"Tani","year":"2022","journal-title":"J. Infect. Chemother."},{"key":"2026043003163586200_R48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224683","article-title":"Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza","volume":"14","author":"Mawatari","year":"2019","journal-title":"PLoS ONE"},{"key":"2026043003163586200_R49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/irv.12794","article-title":"Intravenous peramivir vs oral oseltamivir in high-risk emergency department patients with influenza: results from a pilot randomized controlled study","volume":"15","author":"Hsieh","year":"2021","journal-title":"Influenza Other Respir. Viruses"},{"key":"2026043003163586200_R50","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2147\/IDR.S247421","article-title":"Clinical effectiveness of intravenous peramivir versus oseltamivir for the treatment of influenza in hospitalized patients","volume":"13","author":"Lee","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"2026043003163586200_R51","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa562","article-title":"Clinical effectiveness of intravenous peramivir compared with oseltamivir in patients with severe influenza A with primary viral pneumonia: a randomized controlled study","volume":"8","author":"Chen","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"2026043003163586200_R52","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/14787210.2021.1878025","article-title":"Comparing intravenous peramivir with oral oseltamivir for patients with influenza: a meta-analysis of randomized controlled trials","volume":"19","author":"Fang","year":"2021","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"2026043003163586200_R53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jiac.2021.11.014","article-title":"Comparative effectiveness of neuraminidase inhibitors in patients with influenza: a systematic review and network meta-analysis","volume":"28","author":"Su","year":"2022","journal-title":"J. Infect. Chemother."},{"key":"2026043003163586200_R54","doi-asserted-by":"crossref","first-page":"105281","DOI":"10.1016\/j.antiviral.2022.105281","article-title":"Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020","volume":"200","author":"Govorkova","year":"2022","journal-title":"Antiviral Res."},{"key":"2026043003163586200_R55","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/QCO.0000000000000498","article-title":"Neuraminidase inhibitor resistance in influenza: a clinical perspective","volume":"31","author":"Lee","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"2026043003163586200_R56","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/656802","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial","volume":"51","author":"Watanabe","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"2026043003163586200_R57","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil investigators group. baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2026043003163586200_R58","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/jpids\/piaa145","article-title":"Baloxavir treatment in adolescents with acute influenza: subgroup analysis from the CAPSTONE-1 trial","volume":"10","author":"Portsmouth","year":"2021","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"2026043003163586200_R59","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"2026043003163586200_R60","first-page":"346","article-title":"Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza","volume":"221","author":"Uehara","year":"2020","journal-title":"J. Infect. Dis."},{"key":"2026043003163586200_R61","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/cid\/ciz908","article-title":"Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes","volume":"71","author":"Hirotsu","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"2026043003163586200_R62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103125","article-title":"Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza","volume":"62","author":"Wang","year":"2020","journal-title":"EBioMedicine"},{"key":"2026043003163586200_R63","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1093\/infdis\/jiad409","article-title":"Oral favipiravir exposure and pharmacodynamic effects in adult outpatients with acute influenza","volume":"230","author":"Hayden","year":"2024","journal-title":"J. Infect. Dis."},{"key":"2026043003163586200_R64","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/infdis\/jiac135","article-title":"Favipiravir treatment of uncomplicated influenza in adults: results of two phase 3, randomized, double-blind, placebo-controlled trials","volume":"226","author":"Hayden","year":"2022","journal-title":"J. Infect. Dis."},{"key":"2026043003163586200_R65","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cmi.2024.10.020","article-title":"Efficacy and safety of ZX-7101A, an inhibitor of influenza cap-dependent endonuclease, in adults with uncomplicated influenza: a randomized, double-blind, placebo-controlled phase 2\/3 trial","volume":"31","author":"Wang","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"2026043003163586200_R66","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cmi.2025.01.025","article-title":"Efficacy and safety of single-dose suraxavir marboxil tablet in the treatment of acute uncomplicated influenza in adults: a multi-centre, randomized, double-blind, placebo-controlled phase 2 clinical trial","volume":"31","author":"Wang","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"2026043003163586200_R67","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41591-024-03419-3","article-title":"Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial","volume":"31","author":"Wang","year":"2025","journal-title":"Nat. Med."},{"key":"2026043003163586200_R68","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/infdis\/jiaf075","article-title":"Efficacy and safety of WXSH0208 tablets in treatment of acute uncomplicated influenza infection in adults: a multicenter randomized, double-blind, placebo-controlled phase 2 trial","volume":"232","author":"Cao","year":"2025","journal-title":"J. Infect. Dis."},{"key":"2026043003163586200_R69","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/cid\/ciy874","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"2026043003163586200_R70","doi-asserted-by":"crossref","first-page":"105126","DOI":"10.1016\/j.antiviral.2021.105126","article-title":"Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model","volume":"193","author":"Park","year":"2021","journal-title":"Antiviral Res."},{"key":"2026043003163586200_R71","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0140-6736(24)01307-2","article-title":"Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials","volume":"404","author":"Gao","year":"2024","journal-title":"Lancet"},{"key":"2026043003163586200_R72","first-page":"293","article-title":"Antiviral medications for treatment of nonsevere influenza: a systematic review and network meta-analysis","volume":"185","author":"Gao","year":"2025","journal-title":"J. Am. Med. Assoc. Intern. Med."},{"key":"2026043003163586200_R73","unstructured":"WHO\n          . 2024Clinical practice guidelines for influenza. Guideline. Seehttps:\/\/www.who.int\/publications\/i\/item\/9789240097759 (accessed8-April-2025)."},{"key":"2026043003163586200_R74","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1093\/infdis\/jiaf276","article-title":"Platform trials to assess therapeutics in patients hospitalized with influenza","volume":"232","author":"Waite","year":"2025","journal-title":"J. Infect. Dis."},{"key":"2026043003163586200_R75","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1093\/infdis\/jiaf328","article-title":"Host immunomodulatory interventions in severe influenza","volume":"232","author":"Hui","year":"2025","journal-title":"J. Infect. Dis."},{"key":"2026043003163586200_R76","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(24)01698-2","article-title":"Antiviral treatment and prophylaxis for influenza","volume":"404","author":"Hui","year":"2024","journal-title":"Lancet"},{"key":"2026043003163586200_R77","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jama.2025.25903","article-title":"Influenza A(H3N2) subclade K virus","volume":"335","author":"Zambon","year":"2026","journal-title":"J. Am. Med. Assoc."}],"container-title":["Philosophical Transactions B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/doi\/10.1098\/rstb.2024.0344\/6135591\/rstb.2024.0344.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/doi\/10.1098\/rstb.2024.0344\/6135591\/rstb.2024.0344.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:17:04Z","timestamp":1777533424000},"score":1,"resource":{"primary":{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article\/381\/1949\/20240344\/481548\/Antiviral-treatment-for-influenza"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":77,"journal-issue":{"issue":"1949","published-online":{"date-parts":[[2026,4,30]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1098\/rstb.2024.0344","relation":{},"ISSN":["0962-8436","1471-2970"],"issn-type":[{"value":"0962-8436","type":"print"},{"value":"1471-2970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"20240344"}}